The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.
Pathologie-DNA will implement the anatomic and clinical pathology online support system, which is used to decide which ancillary tests to run on patients.
The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.
The new test would rapidly screen patient samples to determine whether biotin levels are present that could throw off the accuracy of other diagnostic tests.
The companies said that they will combine NeuroFlow’s mental health integration platform and Genomind's Professional PGx Express pharmacogenomics service.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
As part of the agreement, Kindstar will use InCellDx's single-cell immuno-oncology and oncology diagnostic products in China, including Hong Kong and Macao.
They are seeking to determine the concordance between thymidine kinase 1 enzyme concentration in serum and patients' clinical response to treatment.
The firms said that their respective technologies are complementary and bridge a technical gap between pathology, radiology, and oncology.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.